California, USA-based generic drugmaker SOHM says it has signed a sales and marketing agreement to sell its branded generic pharmaceutical products in Africa, although it did not name its new partner.
Sales will begin in Uganda, Tanzania and Zambia under the SOHM brand as soon as the necessary measures have been completed in each country. All of the generic drugs will be produced by SOHM's India-based licensed manufacturing facility, the firm noted.
"Our team has worked diligently to finalize the SOHM brands entry to the African market," stated Shailesh Shah, vice president for corporate strategy at SOHM. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent," he stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze